Radiotherapy & Oncology
Volume 95, Issue 1 , Pages 23-31 , April 2010

Trials and tribulations in charged particle radiotherapy

  • Michael Goitein

      Affiliations

    • Corresponding Author InformationAddress: Ankerstrasse 1, CH-5210 Windisch, AG, Switzerland.

Received 17 March 2009 ,Revised 2 June 2009 ,Accepted 8 June 2009.

References 

  1. Lomax AJ, Bortfeld T, Goitein G, et al. A treatment planning inter-comparison of protons and intensity-modulated photon therapy. Radiother Oncol. 1999;51:257–271
  2. Glimelius B, Ask A, Bjelkengren G, et al. For the Swedish Proton Therapy Centre Project, Number of patients potentially eligible for proton therapy. Acta Oncol. 2005;44:836–849
  3. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol. 2008;26:175–176
  4. Goitein M, Cox JD. Reply to editorials and correspondence regarding randomized clinical trials for proton radiotherapy. J Clin Oncol. 2008;26:2593–2596
  5. Suit H, Kooy H, Trofimov A, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol. 2008;86:148–153
  6. Goitein M. Magical protons?. Int J Radiat Oncol Biol Phys. 2008;70:654–656
  7. Bortfeld T, Jokivarsi K, Goitein M, Kung J, Jiang S. Effects of intra-fraction motion on IMRT dose delivery: statistical analysis and simulation. Phys Med Biol. 2002;47:2203–2220
  8. Gueulette J, Blattmann H, Pedroni E, et al. Relative biologic effectiveness determination in mouse intestine for scanning proton beam at Paul Scherrer Institute, Switzerland. Influence of motion. Int J Radiat Oncol Biol Phys. 2005;62:838–845
  9. Goitein M. The cell’s-eye view: assessing dose in four dimensions. Int J Radiat Oncol Biol Phys. 2005;62:951–953
  10. Mori S, Wolfgang J, Lu H-M, et al. Quantitative assessment of range fluctuations in charged particle lung irradiation. Int J Radiat Oncol Biol Phys. 2008;70:253–261
  11. Urie M, Goitein M, Holley WR, Chen GTY. Degradation of the Bragg peak due to inhomogeneities. Phys Med Biol. 1986;31:1–15
  12. Goitein M. Calculation of the uncertainty in the dose delivered in radiation therapy. Med Phys. 1985;12:608–612
  13. Urie M, Goitein M, Doppke K, et al. The role of uncertainty analysis in treatment planning. Int J Radiat Oncol Biol Phys. 1991;21:91–107
  14. Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties. Phys Med Biol. 2008;53:1027–1042
  15. Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2: the potential effects of inter-fraction and inter-field motions. Phys Med Biol. 2008;53:1043–1056
  16. Urie M, Goitein M, Wagner M. Compensating for heterogeneities in proton radiation therapy. Phys Med Biol. 1984;29:553–566
  17. Gottschalk B. Treatment delivery systems. In:  DeLaney TF,  Kooy HM editor. Proton and charged particle radiotherapy. Philadelphia: Lippincott Williams and Wilkins; 2008;p. 33–40
  18. Tobias CA, Blakely EA, Alpen EL, et al. Molecular and cellular radiobiology of heavy ions. Int J Radiat Oncol Biol Phys. 1982;8:2109–2120
  19. Goitein M. Heavy charged particle radio therapy. Z Med Phys. 2004;14:1–3
  20. Goitein M. Heavy charged particle radio therapy – correspondence. Z Med Phys. 2004;14:201
  21. Goitein M. Future perspectives in charged particle radiotherapy. Riv Med. 2008;14:103–107
  22. Wilkens JJ, Oelfke U. Direct comparison of biologically optimized spread-out Bragg peaks for protons and carbon ions. Int J Radiat Oncol Biol Phys. 2008;70:262–266
  23. Elsässer T, Krämer M, Scholz M. Accuracy of the local effect model for the prediction of biologic effects of carbon ion beams in vitro and in vivo. Int J Radiat Oncol Biol Phys. 2008;71:866–872
  24. Raju MR, et al. A heavy particle comparative study Part III: OER and RBE. Brit J Radiol. 1978;51:712–719
  25. Karger CP, Peschke P, sanchez-Brandelik R, et al. Radiation tolerance of the rat spinal cord after 6 and 18 fractions of photons and carbon ions: experimental results and clinical implications. Int J Radiat Oncol Biol Phys. 2006;66:1488–1497
  26. Paganetti H, Goitein M. Biophysical modeling of proton radiation effects based on amorphous track models. Int J Radiat Biol. 2001;77:911–928
  27. Duncan W. An evaluation of the results of neutron therapy trials. Acta Oncol. 1994;33:299–306
  28. Schulz-Ertner D, Nikoghosyan A, Hof H, et al. Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys. 2007;67:171–177
  29. Schulz-Ertner D, Karger CP, Feuerhake A, et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys. 2007;68:449–457
  30. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953–964
  31. Goitein M, Jermann M. The relative costs of proton and X-ray radiation therapy. Clin Oncol. 2003;15:S37–S50
  32. Sengbuscha E, Pérez-Andújar A, DeLuca PM, Mackie TR. Maximum proton kinetic energy and patient-generated neutron fluence considerations in proton beam arc delivery radiation therapy. Med Phys. 2009;36:364–372
  33. Olsen DR, Bruland ØS, Frykholm G, et al. Proton therapy – a systematic review of clinical effectiveness. Radiother Oncol. 2007;83:123–132
  34. Lodge M, Pils-Johannesma M, Stirk L, et al. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol. 2007;83:110–122
  35. Glimelius B, Montelius A. Do we need the randomized trials and can we do them?. Radiother Oncol. 2007;83:105–109
  36. Brada M, Pils-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007;25:965–970
  37. Hellman S, Hellman DS. Of mice but not men. Problems of the randomized clinical trial. N Engl J Med. 1991;324:1585–1589
  38. Freedman B. Equipoise and the ethics of clinical research. N Eng J Med. 1987;317:141–145
  39. Tepper J. Protons and parachutes. J Clin Oncol. 2008;26:2436–2437
  40. Glatstein E, Glick J, Kaiser L, Hahn SM. Should randomized trials be required for proton radiotherapy? An alternative view. J Clin Oncol. 2008;26:2438–2439
  41. Lewis B. On equipoise and emerging technologies. J Clin Oncol. 2008;26:2590
  42. Macbeth F, Williams M. Proton therapy should be tested in randomised trials. J Clin Oncol. 2008;26:2590–2591
  43. Morgan JP, Min D. A patient’s perspective on randomized clinical trials (RCTs) for proton radiotherapy. J Clin Oncol. 2008;26:2592
  44. Brada M, De Ruysscher D, Pijls-Joannesma M. Evidence for proton therapy. J Clin Oncol. 2008;26:2592–2593
  45. Bentzen SM. Randomized controlled trials in health technology assessment: overkill or overdue?. Radiother Oncol. 2008;86:142–147
  46. Goitein M, Goitein G. Swedish protons. Acta Oncol. 2005;44:793–797
  47. International Commission on Radiation Units and Measurements, Prescribing, Recording, and Reporting Proton Beam Therapy, In Journal of the ICRU, Report 78. Oxford: Oxford University Press; 2007. p. 21–8.
  48. Goitein M. How best to dispose of extra-tumoral dose: a cautionary note for IMRT. Int J Radiat Oncol Biol Phys. 2009;75:1–3
  49. Ask A, Johansson B, Glimelius B. The potential of proton beam therapy in gastrointestinal cancer. Acta Oncol. 2005;44:896–903

☆ Delivered as the 29th Elis Berven lecture at the 2009 annual meeting of the Swedish Society of Oncology.

PII: S0167-8140(09)00316-8

doi: 10.1016/j.radonc.2009.06.012

Radiotherapy & Oncology
Volume 95, Issue 1 , Pages 23-31 , April 2010

Article Tools

* Image Usage & Resolution